Stanford researchers have developed a method that not only detects B- and T-cell cancers but also is sufficiently sensitive to detect residual cancer in patients.
Stanford researchers in the Onori Lab have developed a battery management system (BMS) that uses sine-wave current pulses to accurately determine a battery's state-of-charge (SOC).
Researchers at Stanford have developed the paperfuge- an ultra-low cost (20 cents), light weight (2g) field portable centrifuge (125,000 rpm; 30,000 g RCF) made out of paper that runs on human power.
In the presence of intra-fraction organ motion, target localization uncertainty can hamper the advantage of using highly conformal dose techniques such as intensity modulated radiation therapy (IMRT).
Stanford researchers have created a novel wearable device and system to assess fatigue on the user based on electrical activity associated with an eye blink of the subject.
Researchers in Dr. Anton Wyss-Coray's lab have identified a new therapeutic avenue for treatment of age-related neurodegenerative diseases. Cerebrovascular changes and inflammation are key features of brain aging and neurodegeneration.
Researchers at Stanford have developed a gene expression-based method for determining a virally infected patient's risk of developing severe symptoms, irrespective of the virus.
Alloreaction-associated antigen (ARAg) is a novel member of the immunoglobulin superfamily. This invention's issued US patent claims composition of matter of ARAg polypeptides and nucleic acids encoding ARAg polypeptides.
Multiplexed analysis of biological components is critical for classifying molecular subtypes of heterogeneous tumors to provide patient-specific therapies.
Stanford inventors have developed a novel diagnostic tool that identifies distinct immune signatures in the peripheral blood of osteoarthritis patients using mass cytometry (CyTOF) and applied machine learning.
Researchers at Stanford have developed a clinically applicable method of bone marrow conditioning for stem cell transplantation or treatment of hematologic malignancies.
Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.
Stanford researchers have developed a novel catheter technology for sensing embolic delivery and reflux as a strategy to eliminate need for X-ray imaging during angiography.